Compared to phosphodiesterase-5 inhibitor (PDE5i) or combination endothelin-receptor antagonist (ERA)/PDE5i, initial therapy with an ERA in SSc-PAH patients was associated with a significantly worse time to clinical worsening. PubMed, Arthritis Rheumatol, 10/19/2015. (Also see PHAROS)
This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.